ArticleScientific reports2025

Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson's disease with the first-in-class adaptive peptide AmyP53.

Jacques Fantini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.